US 11,766,431

Application 17/245,209 · Granted Sep 26, 2023

New therapeutical composition containing apomorphine as active ingredient

Estimated expiration

July 11, 2032

5y 234d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Could not fetch continuity data for application PCTEP2012002916: Resource not found (404)
Earliest effective filing
Jul 11, 2012
+ 20 years
Jul 11, 2032
PTA +213d
Feb 9, 2033
TD cap (US 11,026,938)
Jul 11, 2032
Final
Jul 11, 2032

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
April 30, 2021
Earliest effective filing
July 11, 2012
Issue date
September 26, 2023
PTA
+213 days
Base expiry (before PTA)
July 11, 2032

July 11, 2012 + 20 years = July 11, 2032 + 213 PTA days = February 9, 2033

  • Continuation of application 14/152,000, filed Jan 10, 2014, issued as US 11,026,938
  • Continuation of application PCTEP2012002916, filed Jul 11, 2012
  • Continuation of application PCTEP2012002916, filed Jul 11, 2012

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to July 11, 2032 (earliest expiring referenced patent: US 11,026,938)

  • US 11,026,938· Application 14/152,000Capping patent

    New therapeutical composition containing apomorphine as active ingredient

    Filing date
    Jan 10, 2014
    Earliest effective filing
    Jul 11, 2012
    Issue date
    Jun 8, 2021
    PTA
    0 days
    Calculated expiration
    Jul 11, 2032

    Continuation of PCTEP2012002916, filed Jul 11, 2012

    Jul 11, 2012 + 20y = Jul 11, 2032

  • US 11,766,431· Application 17/245,209(from application 17/245,209)

    New therapeutical composition containing apomorphine as active ingredient

    Filing date
    Apr 30, 2021
    Earliest effective filing
    Jul 11, 2012
    Issue date
    Sep 26, 2023
    PTA
    +213 days
    Calculated expiration
    Feb 9, 2033

    Continuation of 14/152,000, filed Jan 10, 2014, issued as US 11,026,938

    Continuation of PCTEP2012002916, filed Jul 11, 2012

    Continuation of PCTEP2012002916, filed Jul 11, 2012

    Jul 11, 2012 + 20y + 213d PTA = Feb 9, 2033

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/245,209 · US 11,766,431

PatentReply compiles the prosecution history behind US 11,766,431: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US11766431

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.